title: [Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin: case report].
abstract: Interferon is an immunomodulating cytokine used to treat patients with different diseases, such as hepatitis C chronic infection. Pegylated interferon is a new type of interferon, developed to increase the half-life of the drug. Many side effects have been related to its use, including ocular toxicity and retinopathy. The most reported ocular findings are cotton-wool spots and hemorrhages located at the posterior pole and surrounding optic nerve head. We describe one case of pegylated interferon-associated retinopathy with visual loss. The patient had visual acuity improvement four weeks after discontinuation of the medication and the ocular findings became much more subtle.
authors.affiliation: Centro Brasileiro de Cirurgia de Olhos, Goiânia (GO), Brazil.
authors.forename: Marcos Pereira de
authors.initials: MP
authors.lastname: Avila
authors.forename: André Moraes
authors.initials: AM
authors.lastname: Freitas
authors.forename: David Leonardo Cruvinel
authors.initials: DL
authors.lastname: Isaac
authors.forename: André Luis de Moura
authors.initials: AL
authors.lastname: Bastos
authors.forename: Rafael Valadares
authors.initials: RV
authors.lastname: Pena
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced*; D012254:Ribavirin / Q000009:adverse effects*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin